Hexarelin Acetate | Buy Research-Grade Hexarelin in Europe | ≥99% Purity

Hexarelin Acetate is a synthetic hexapeptide growth hormone secretagogue and potent GHS-R1a agonist, available to buy in Europe for laboratory research into growth hormone secretagogue receptor pharmacology, GH pulse biology, cardioprotection, ghrelin receptor signalling, and the comparative pharmacology of synthetic peptide GH secretagogues.

Laboratories and research institutions across the EU can order verified, research-grade Hexarelin Acetate with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA)

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to EU & Europe | Tracked Shipping

What is Hexarelin Acetate?

Hexarelin Acetate is a synthetic hexapeptide — sequence His-D-2-MePhe-Ala-Trp-D-Phe-Lys-NH2 — belonging to the growth hormone-releasing peptide (GHRP) family of synthetic GHS-R1a agonists. Developed at Europeptides and characterised through the collaborative research of Bowers, Deghenghi, and colleagues in the 1990s, Hexarelin was designed as an optimised high-potency GHRP — incorporating the D-2-methylphenylalanine (D-2-MePhe) substitution at position 2 that distinguishes it from other GHRPs and confers its exceptional GHS-R1a binding affinity and GH-releasing potency.

Hexarelin belongs to the same synthetic peptide GH secretagogue family as GHRP-6 and GHRP-2 — sharing the core Met-enkephalin-derived pharmacophore that enables GHS-R1a engagement — but is characterised as the most potent GH-releasing peptide in the GHRP series on a molar basis. Its GHS-R1a agonism drives pulsatile GH release from pituitary somatotrophs through the same ghrelin receptor pathway activated by endogenous ghrelin — making Hexarelin a high-potency research tool for studying GH secretagogue receptor biology, GH pulse physiology, and the downstream consequences of pharmacological GHS-R1a activation.

Beyond its classical GHS-R1a-mediated GH-releasing activity, Hexarelin has been characterised as the first GHRP to demonstrate significant GHS-R1a-independent cardioprotective effects — binding the CD36 scavenger receptor in cardiac tissue and producing direct cardiac protection through GH-independent mechanisms. This cardioprotective profile — documented across ischaemia-reperfusion models, heart failure models, and isolated heart preparations — has established Hexarelin as a uniquely important research tool in the GHRP class, providing both reference GHS-R1a pharmacology and a GH-independent CD36-mediated cardiac biology research application that distinguishes it from all other peptide GH secretagogues. These properties have made Hexarelin one of the most scientifically significant and research-active peptide GH secretagogues available to European laboratories.

What Does Hexarelin Acetate Do in Research?

In laboratory settings, Hexarelin is studied across GH secretagogue receptor pharmacology, pituitary biology, cardiac research, and comparative GHRP pharmacology. EU and European researchers working with Hexarelin Acetate typically focus on:

• GHS-R1a receptor pharmacology — Hexarelin is the highest-potency synthetic peptide GHS-R1a agonist in the GHRP class — making it the reference high-affinity tool for GH secretagogue receptor binding studies, receptor activation assays, downstream signalling characterisation, and comparative GHRP potency benchmarking in ghrelin receptor pharmacology research.
• GH pulse biology and somatotroph research — Hexarelin drives robust pulsatile GH release from pituitary somatotroph cells through GHS-R1a/Gq-coupled IP3/calcium signalling — synergising with endogenous GHRH to produce amplified GH pulses. Studies use Hexarelin to examine GH secretagogue receptor-mediated somatotroph activation, GH pulse amplitude regulation, and the pituitary biology of GH secretion.
• Cardioprotection and cardiac biology research — Hexarelin’s CD36-mediated cardioprotective effects have been documented across multiple cardiac injury models — including ischaemia-reperfusion, doxorubicin-induced cardiotoxicity, and heart failure models — through mechanisms independent of GH release. Studies use Hexarelin to examine CD36 receptor biology in cardiac tissue and GH-independent peptide cardioprotection mechanisms.
• CD36 receptor biology — Hexarelin was the first peptide ligand identified for the CD36 scavenger receptor in cardiac tissue — a finding that opened a new research area examining CD36 as a cardioprotective signal receptor beyond its established role in fatty acid uptake and oxLDL recognition. Studies use Hexarelin to characterise CD36 signalling in cardiomyocytes and the downstream cardioprotective mechanisms activated through this receptor.
• Ghrelin receptor signalling research — GHS-R1a is the receptor through which endogenous ghrelin drives GH release, appetite stimulation, and energy homeostasis. Hexarelin’s high-affinity GHS-R1a agonism makes it a powerful tool for studying ghrelin receptor-mediated intracellular signalling — including Gq/IP3/calcium and Gi/cAMP pathway activation, receptor internalisation kinetics, and downstream gene expression programmes in GHS-R1a-expressing cell systems.
• Comparative GHRP potency and pharmacology research — Hexarelin is systematically studied alongside GHRP-2, GHRP-6, Ipamorelin, and other GH secretagogues in comparative pharmacology studies — with its higher GHS-R1a affinity and distinct D-2-MePhe structural feature providing reference high-potency GHS-R1a data against which other GHRP compounds are benchmarked.
• Cortisol and prolactin co-stimulation research — like GHRP-2 but with even greater potency, Hexarelin drives co-stimulation of cortisol and prolactin alongside GH — through mechanisms involving both GHS-R1a activation and hypothalamic CRH pathway engagement. Studies examining the differential HPA axis and lactotroph effects of GHRPs use Hexarelin as the reference high-potency compound to examine the relationship between GHS-R1a engagement strength and co-secretagogue activity.
• GH axis and IGF-1 biology — GH released by Hexarelin-driven somatotroph activation drives hepatic IGF-1 production — the primary mediator of GH’s anabolic and growth-promoting effects. Studies examining the GH/IGF-1 axis use Hexarelin as a pharmacological GH-releasing tool to examine the downstream consequences of GH pulse amplitude elevation on IGF-1 production, IGF-1 receptor signalling, and the metabolic and anabolic effects of GH axis activation.
• Heart failure model research — studies have examined Hexarelin in pre-clinical heart failure models — documenting improvements in cardiac function parameters including ejection fraction, fractional shortening, and myocardial fibrosis through mechanisms that include both GH-dependent and CD36-mediated GH-independent cardioprotective pathways. These heart failure findings have established Hexarelin as one of the most cardioprotection-relevant peptides in the GHRP research literature.
• Appetite and energy homeostasis research — GHS-R1a activation by Hexarelin engages the ghrelin receptor’s appetite-stimulating and energy homeostasis-regulating functions — including orexigenic signalling in the hypothalamic arcuate nucleus. Studies examining ghrelin receptor contributions to appetite regulation and energy homeostasis use Hexarelin as a high-potency GHS-R1a agonist tool in these research applications.
• Ischaemia-reperfusion injury models — Hexarelin has been examined in cardiac ischaemia-reperfusion injury models — documenting protection of cardiomyocyte viability, reduction of infarct size, and preservation of cardiac function following ischaemic injury through its combined GHS-R1a-mediated and CD36-mediated cardioprotective mechanisms. These findings have made Hexarelin the reference cardioprotective GHRP in ischaemia-reperfusion research.
• Receptor desensitisation and tachyphylaxis research — repeated GHS-R1a stimulation produces receptor desensitisation and attenuated GH responses — a phenomenon characterised across the GHRP class. Hexarelin’s high GHS-R1a potency makes it a useful tool for studying the kinetics of GHS-R1a desensitisation, receptor internalisation, and recovery — contributing to understanding of opioid and peptide receptor desensitisation mechanisms in the broader GPCR biology literature.

All research applications are for in vitro and pre-clinical use only.

What Do Studies Say About Hexarelin Acetate?

Hexarelin has a well-developed and scientifically significant research literature — with studies establishing its position as the highest-potency GHRP, characterising its unique CD36-mediated cardioprotective properties, and documenting its broad GH secretagogue pharmacological profile.

GH-releasing potency characterisation: Foundational studies comparing Hexarelin to GHRP-6 and GHRP-2 consistently documented Hexarelin’s superior GH-releasing potency on a molar basis — establishing it as the most potent synthetic peptide GH secretagogue in the GHRP class. These comparative GH-releasing studies characterised the pharmacodynamic superiority of the D-2-MePhe substitution for GHS-R1a engagement and established Hexarelin as the reference high-potency GHRP for subsequent comparative pharmacology research.

CD36 cardioprotection discovery: The landmark finding that Hexarelin binds CD36 in cardiac tissue — producing cardioprotective effects independent of GH release — was one of the most significant discoveries in peptide GH secretagogue research. Studies by Bodart, Marleau, and colleagues characterised CD36 as a novel cardiac Hexarelin receptor — documenting protection against ischaemia-reperfusion injury, preservation of cardiac function, and anti-fibrotic effects through GH-independent CD36-mediated signalling. This discovery established a new research paradigm for GH-independent GHRP cardioprotection biology.

Heart failure research: Studies examining Hexarelin in pre-clinical heart failure models documented significant improvements in cardiac function parameters — including ejection fraction and fractional shortening — alongside reductions in myocardial fibrosis and cardiomyocyte apoptosis. The combined GH-dependent and CD36-mediated GH-independent contributions to these cardiac functional improvements have been characterised in studies using GH-deficient animals and GH receptor-deficient cell systems to dissect the relative contributions of each pathway.

Ischaemia-reperfusion protection: Pre-clinical studies in cardiac ischaemia-reperfusion models consistently documented Hexarelin-associated reductions in infarct size, preservation of left ventricular function, and reduced cardiomyocyte apoptosis following ischaemic injury — with findings establishing the CD36 pathway as essential for GH-independent cardioprotection and the GHS-R1a/GH pathway contributing additional protective effects through IGF-1-mediated cardiomyocyte survival signalling.

Comparative GHRP pharmacology: Studies systematically comparing Hexarelin to GHRP-2, GHRP-6, and Ipamorelin have characterised Hexarelin’s superior GHS-R1a binding affinity, its greater cortisol and prolactin co-stimulation compared to Ipamorelin, and its unique CD36-mediated cardioprotective profile — establishing Hexarelin’s pharmacological position within the GHRP class and providing the reference data for subsequent comparative GH secretagogue research.

Receptor desensitisation research: Studies examining Hexarelin-induced GHS-R1a desensitisation characterised the kinetics and molecular mechanisms of repeated GHRP stimulation-associated attenuation of GH responses — documenting receptor internalisation, uncoupling from G-protein, and the time course of GHS-R1a resensitisation. These desensitisation findings have contributed to understanding of GPCR regulatory mechanisms in the context of GH secretagogue receptor biology.

Cortisol and prolactin co-stimulation: Comparative studies characterising Hexarelin’s HPA axis and lactotroph co-stimulation documented significant cortisol and prolactin responses alongside GH release — with findings establishing that higher GHS-R1a potency correlates with greater co-secretagogue activity and providing mechanistic context for the cortisol elevation distinguishing high-potency GHRPs from the more GH-selective Ipamorelin.

Hexarelin vs Related Growth Hormone Secretagogue Research Compounds

Compound	Sequence Features	GHS-R1a Potency	Cortisol/Prolactin	CD36 Activity	Key Research Distinction
Hexarelin	D-2-MePhe² substitution	Highest in GHRP class	Significant	Yes — unique	Highest potency GHRP, CD36 cardioprotection
GHRP-2	D-β-Nal² substitution	Very high	Significant	Not characterised	High potency — strong HPA co-stimulation
GHRP-6	D-Trp² — parent GHRP	High	Moderate	Not characterised	Reference GHRP, appetite biology
Ipamorelin	Aib³ — selectivity-optimised	Moderate-high	Minimal	Not characterised	Most GH-selective GHRP — minimal co-stimulation
MK-677	Non-peptide GHS-R1a agonist	High — oral bioavailable	Moderate	Not characterised	Oral administration research tool
CJC-1295	GHRH analogue — DAC	GHRH pathway	None	Not characterised	GHRH receptor — synergy with GHRPs

Buying Hexarelin Acetate in Europe — What’s Included

Every order of Hexarelin Acetate dispatched to EU and European research institutions includes:

• Batch-Specific Certificate of Analysis (CoA)
• HPLC Chromatogram
• Mass Spectrometry Confirmation
• Sterility and Endotoxin Testing Reports
• Reconstitution Protocol
• Technical Research Support

Frequently Asked Questions — Hexarelin Acetate EU

Can I Buy Hexarelin Acetate in the EU and Europe?

Yes. We supply research-grade Hexarelin Acetate with fast tracked dispatch to all EU member states and wider European destinations. All orders include full batch documentation. Hexarelin is supplied strictly for laboratory research use only.

What Makes Hexarelin More Potent Than Other GHRPs?

The D-2-methylphenylalanine (D-2-MePhe) substitution at position 2 confers Hexarelin’s superior GHS-R1a binding affinity compared to the D-Trp² of GHRP-6 and D-β-Nal² of GHRP-2. This structural modification optimises the peptide backbone conformation for high-affinity GHS-R1a engagement — producing the highest GH-releasing potency in the synthetic peptide GHRP class on a molar basis.

What is CD36 and Why is Hexarelin’s CD36 Activity Research-Significant?

CD36 is a scavenger receptor expressed in cardiac tissue, macrophages, and adipocytes — classically studied for its roles in fatty acid uptake and oxidised LDL recognition. Hexarelin’s discovery as the first peptide ligand for CD36 in cardiac tissue opened a new research dimension — demonstrating that GHRPs can produce cardioprotective effects entirely independent of GH release through CD36-mediated signalling. This GH-independent cardioprotection mechanism distinguishes Hexarelin from all other GHRPs.

What is the Difference Between Hexarelin and Ipamorelin?

Both are GHS-R1a agonists but with contrasting selectivity profiles. Hexarelin is the highest-potency GHRP with significant cortisol, prolactin, and ACTH co-stimulation alongside GH release and unique CD36 cardioprotective activity. Ipamorelin is the most GH-selective GHRP — with minimal cortisol or prolactin co-stimulation. The two represent the extreme ends of the GHRP selectivity spectrum — Hexarelin for high-potency broad GHS-R1a biology, Ipamorelin for selective GH axis research.

Why Does Hexarelin Cause Greater Cortisol Co-Stimulation Than Other GHRPs?

Hexarelin’s higher GHS-R1a potency produces stronger hypothalamic activation — including engagement of GHS-R1a expressing CRH neurons — driving greater HPA axis co-activation alongside pituitary GH release. Studies have documented that GHRP-induced cortisol co-stimulation correlates with GHS-R1a engagement potency across the GHRP class — with Hexarelin at the high end and Ipamorelin producing minimal HPA co-activation due to its selectivity-optimised structure.

What is the Difference Between Hexarelin and GHRP-2?

Both are high-potency GHRPs with significant cortisol and prolactin co-stimulation. Hexarelin has the D-2-MePhe² substitution producing superior GHS-R1a affinity and GH-releasing potency compared to GHRP-2’s D-β-Nal² substitution. Hexarelin additionally has the characterised CD36 cardioprotective activity not documented for GHRP-2 — making Hexarelin the preferred tool when both GHS-R1a and CD36 biology are relevant to the research question.

How Does Hexarelin Synergise With GHRH Analogues in Research?

GHRPs and GHRH act on complementary pituitary pathways — GHRPs through GHS-R1a/Gq/calcium and GHRH through GHRH-R/Gs/cAMP — producing synergistic GH release when combined that significantly exceeds either alone. Hexarelin’s high GHS-R1a potency produces particularly robust synergy with GHRH analogues such as CJC-1295 — making Hexarelin/GHRH combination protocols a research tool for studying maximal pharmacological GH axis stimulation and the mechanistic basis of GHRP/GHRH synergy.

How Do I Reconstitute Hexarelin Acetate for Laboratory Use?

Reconstitute with sterile water or appropriate laboratory buffer by adding solvent slowly down the vial wall and swirling gently. Hexarelin reconstitutes readily in aqueous buffers without organic co-solvents. Prepare at required concentration, aliquot, and store at -80°C to minimise freeze-thaw degradation. Standard peptide handling protocols apply.

How Quickly is Hexarelin Delivered to Europe?

Delivery to EU and European destinations typically takes 3–7 working days via tracked international courier with packaging maintaining peptide stability throughout transit.

Product Specifications

Parameter	Detail
Sequence	His-D-2-MePhe-Ala-Trp-D-Phe-Lys-NH2
Salt Form	Acetate salt
Type	Synthetic Hexapeptide GH Secretagogue — GHRP Class
Key Structural Feature	D-2-methylphenylalanine at position 2
Primary Receptor	GHS-R1a (Ghrelin Receptor) — highest potency GHRP
Secondary Receptor	CD36 — GH-independent cardioprotection
GH Potency	Highest in synthetic peptide GHRP class
Cortisol/Prolactin Co-stimulation	Significant
Primary Research Interest	GHS-R1a pharmacology, GH pulse biology, cardioprotection, CD36 biology
Purity	≥99%
Verification	HPLC & Mass Spectrometry
Form	Sterile Lyophilised Powder
Solubility	Sterile water or laboratory buffer
Storage	-20°C, protected from light and moisture
Intended Use	Research use only

Research Disclaimer

Hexarelin Acetate is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.